midi microdosing glp 1 Why GLP-1 Microdosing? A Closer Look at Reported Benefits The microdosing trend with GLP-1

Injections that go directly into the bloodstream bypass absorption barriers according to the National Institutes of Health (NIH) and can help people with malabsorption issues like those who have intestinal disorders or have undergone intestinal surgeries

Long-term use of GLP-1 medications has been associated with sustained weight loss, improved glycemic control, and beneficial cardiovascular outcomes

[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)

For the latter, some data show that diarrhea affects up to 10% of users